Kathryn Balmanno

3.9k citations

45 papers · 3.2k indexed · 1 hit paper · h-index 25

Co-authors: Simon J. Cook Kathryn Hadfield Claire R. Weston Rebecca Gilley Katherine Ewings Annette S. Little Matthew J. Sale Paul D. Smith
Topics: Melanoma and MAPK Pathways (18 papers)Cell death mechanisms and regulation (11 papers)Protein Kinase Regulation and GTPase Signaling (10 papers)
Cited by: Oncology Molecular Biology Cancer Research
Journals: Science Journal of Biological Chemistry Nature Communications
Partner nations: United Kingdom United States Australia

In The Last Decade

Kathryn Balmanno

45 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, Bim

2003 511 citations Kathryn Balmanno, Kathryn Hadfield et al. Journal of Biological Chemistry profile →

Peers

Countries citing papers authored by Kathryn Balmanno

Since Specialization

Citations

This map shows the geographic impact of Kathryn Balmanno's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kathryn Balmanno with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kathryn Balmanno more than expected).

Fields of papers citing papers by Kathryn Balmanno

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kathryn Balmanno. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kathryn Balmanno. The network helps show where Kathryn Balmanno may publish in the future.

Co-authorship network of co-authors of Kathryn Balmanno

This figure shows the co-authorship network connecting the top 25 collaborators of Kathryn Balmanno. A scholar is included among the top collaborators of Kathryn Balmanno based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kathryn Balmanno. Kathryn Balmanno is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ERK1/2 inhibitors act as monovalent degraders inducing ubiquitylation and proteasome-dependent turnover of ERK2, but not ERK1 2023 ·Biochemical Journal ·Kathryn Balmanno,Andrew M. Kidger,Dominic P. Byrne,Matthew J. Sale,(unknown),Patrick A. Eyers,Simon J. Cook	6
2	Dual-Mechanism ERK1/2 Inhibitors Exploit a Distinct Binding Mode to Block Phosphorylation and Nuclear Accumulation of ERK1/2 2019 ·Molecular Cancer Therapeutics ·Andrew M. Kidger,Joanne M. Munck,Harpreet K. Saini,Kathryn Balmanno,(unknown),Aurélie Courtin,Brent Graham,Marc O’Reilly,(unknown),Simon J. Cook	17
3	Resistance to ERK1/2 pathway inhibitors; sweet spots, fitness deficits and drug addiction 2019 ·Cancer Drug Resistance ·Matthew J. Sale,Kathryn Balmanno,Simon J. Cook	5
4	MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance 2019 ·Nature Communications ·Matthew J. Sale,Kathryn Balmanno,(unknown),Eiko Ozono,Katarzyna Wojdyła,Rebecca E. McIntyre,Rebecca Gilley,(unknown),Karen Howarth,Gareth Hughes,Jonathan R. Dry,Mark J. Arends,Pilar Caro,David Oxley,Susan Ashton,David J. Adams,Julio Sáez-Rodríguez,Paul D. Smith,Simon J. Cook	41
5	Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome 2015 ·Cellular and Molecular Life Sciences ·(unknown),Tom Dunkley,Mark Cockerill,Rachel Rowlinson,(unknown),(unknown),Kathryn Balmanno,Louise Goodwin,Richard A. Ward,Pamela A. Lochhead,Sylvie M. Guichard,Kevin Hudson,Simon J. Cook	27
6	Adaptation to mTOR kinase inhibitors by amplification of eIF4E to maintain cap-dependent translation 2013 ·Journal of Cell Science ·(unknown),Rebecca Gilley,Kathryn Balmanno,Matthew J. Sale,Karen Howarth,(unknown),Paul D. Smith,Sylvie M. Guichard,Simon J. Cook	66
7	Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance 2012 ·Oncogene ·(unknown),Kathryn Balmanno,Annette S. Little,Michael Wilson,Simon Andrews,(unknown),(unknown),Paul R. Gavine,Simon J. Cook	120
8	Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY‐142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines 2009 ·International Journal of Cancer ·Kathryn Balmanno,Simon Chell,(unknown),Shaista Hayat,Simon J. Cook	115
9	The duration of ERK1/2 activity determines the activation of c-Fos and Fra-1 and the composition and quantitative transcriptional output of AP-1 2006 ·Cellular Signalling ·(unknown),Rebecca Gilley,H. Nikki March,Kathryn Balmanno,Simon J. Cook	52
10	ERK1/2 and p38 cooperate to induce a p21CIP1-dependent G1 cell cycle arrest 2004 ·Oncogene ·Daniel E. Todd,Ruth M. Densham,Sarah A Molton,Kathryn Balmanno,(unknown),Claire R. Weston,Andrew P. Garner,(unknown),Simon J. Cook	74
11	Extracellular Signal-regulated Kinases 1/2 Are Serum-stimulated “BimEL Kinases” That Bind to the BH3-only Protein BimEL Causing Its Phosphorylation and Turnover 2004 ·Journal of Biological Chemistry ·(unknown),Katherine Ewings,Kathryn Hadfield,E. A. Howes,Kathryn Balmanno,Simon J. Cook	173
12	Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells 1999 ·Oncogene ·Kathryn Balmanno,Simon J. Cook	195
13	The relationship between intrinsic thymidylate synthase expression and sensitivity to THYMITAQTM in human leukaemia and colorectal carcinoma cell lines 1997 ·British Journal of Cancer ·EJ Estlin,Kathryn Balmanno,A H Calvert,Andrew G. Hall,John Lunec,DR Newell,A D Pearson,G. A. Taylor	3
14	Pharmacokinetics and pharmacodynamics of prolonged oral etoposide in women with metastatic breast cancer 1995 ·Cancer Chemotherapy and Pharmacology ·Michael Millward,David R. Newell,Kally Yuen,Jane Matthews,Kathryn Balmanno,(unknown),Lindsey Gumbrell,Michael Lind,Fiona Chapman,(unknown),(unknown),Brian M.J. Cantwell,A. Hilary Calvert	18
15	Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481) 1995 ·European Journal of Cancer ·Michael Millward,David R. Newell,(unknown),Linus N. Igwemezie,Kathryn Balmanno,(unknown),Lindsey Gumbrell,Michael Lind,(unknown),(unknown),(unknown),B.M.J. Cantwell,G. A. Taylor,(unknown),Benjamin Winograd,Sanjeev Kaul,(unknown),A H Calvert	12
16	Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results 1993 ·Cancer Treatment Reviews ·A H Calvert,Michael Lind,(unknown),B.M.J. Cantwell,Lindsey Gumbrell,(unknown),(unknown),(unknown),Andrew Robinson,(unknown),Kathryn Balmanno,David R. Newell	30
17	Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group. 1993 ·Journal of Clinical Oncology ·David R. Newell,A D Pearson,Kathryn Balmanno,L Price,Ruth Wyllie,M.J. Keir,A. Hilary Calvert,Ian Lewis,CR Pinkerton,Michaël C.G. Stevens	113
18	Phase II trial of trimelamol in refractory ovarian cancer 1991 ·British Journal of Cancer ·(unknown),A H Calvert,M. Gore,Kathryn Balmanno,(unknown),Timothy Perren,E. Wiltshaw	8
19	Estimation of the In Vitro and In Vivo Inhibitory Effects of Antifolates upon Thymidylate Synthase (TS) in Whole Cells 1989 ·Advances in experimental medicine and biology ·Geoffrey A. Taylor,A L Jackman,Kathryn Balmanno,L. R. HUGHES,A. Hilary Calvert	12
20	BIOLOGICAL PROPERTIES OF 2-DESAMINO-2 SUBSTITUTED -5,8-DEAZAFOLATES THAT INHIBIT THYMIDYLATE SYNTHASE (TS) 1988 ·UCL Discovery (University College London) ·(unknown),(unknown),(unknown),(unknown),Graham M. F. Bisset,(unknown),Kathryn Balmanno,(unknown),(unknown)	3

About Kathryn Balmanno

Kathryn Balmanno is a scholar working on Oncology, Molecular Biology and Cell Biology, having authored 45 papers that have together received 3.2k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (18 papers), Cell death mechanisms and regulation (11 papers) and Protein Kinase Regulation and GTPase Signaling (10 papers). The work is most often cited by research in Oncology (956 citations), Molecular Biology (2.4k citations) and Cancer Research (375 citations). Kathryn Balmanno has collaborated with scholars based in United Kingdom, United States and Australia. Frequent co-authors include Simon J. Cook, Kathryn Hadfield, Claire R. Weston, Rebecca Gilley, Katherine Ewings, Annette S. Little, Matthew J. Sale, Paul D. Smith, Ceri M. Wiggins and E. A. Howes. Their work appears in journals such as Science, Journal of Biological Chemistry and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact